Table 1 Baseline demographic and clinical characteristics of patients with benign MS based on 3 classification criteria
From: Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC)
Variable | EDSS ≤2, DD ≥10a (Criterion I) | EDSS ≤3, DD ≥15 (Criterion II) | EDSS ≤3, DD ≥10 (Criterion III) |
|---|---|---|---|
Patients, n (%)b | 1237 (19.8) | 1253 (20.0) | 2081 (33.3) |
Female, % | 79.6 | 78.5 | 77.4 |
Race, % Caucasian/Hispanic-American African-American Other | 94.6 3.8 1.6 | 95.3 3.6 1.1 | 94.2 4.3 1.3 |
Family history,% | 19.5 | 20.6 | 20.2 |
Age at onset, y, mean (SD) | 30.2 (8.5) | 29.3 (8.6) | 30.8 (8.9) |
Age at baseline, y, mean (SD) | 47.8 (9) | 51.9 (9) | 49.3 (9.5) |
EDSS, mean (SD) | 1.4 (0.6) | 2.1 (0.8) | 2.0 (0.8) |
EDSS, median (range) | 1.5 (0–2.0) | 2.0 (0–3.0) | 2.0 (0–3.0) |
Disease duration, y, mean (SD) | 17 (6.7) | 22 (6.9) | 17.9 (7.3) |
Disease course, % Relapsing-remitting Secondary-progressive Progressive-relapsing Primary-progressive | 95.6 2.7 0.6 1.1 | 86.4 9.3 1.8 2.5 | 88.4 7.5 1.5 2.6 |
On DMT at enrollment, n (%)c | 505 (40.8) | 481 (38.4) | 848 (40.7) |
Type of DMT, n (%) Interferon beta-1a IM Interferon beta-1b SC Interferon beta-1a SC Glatiramer acetate Methotrexate Myelin (oral) Mitoxantrone Azathioprine Cyclophosphamide Immunoglobulin (intravenous) Linomide | 314 (62.2) 98 (19.4) 1 (0.2) 64 (12.7) 8 (1.6) 13 (2.6) 0 3 (0.6) 1 (0.2) 2 (0.4) 1 (0.2) | 300 (62.4) 90 (18.7) 1 (0.2) 59 (12.3) 12 (2.5) 11 (2.3) 0 5 (1.0) 1 (0.2) 1 (0.2) 1 (0.2) | 515 (60.7) 164 (19.3) 3 (0.4) 107 (12.6) 19 (2.2) 24 (2.8) 0 7 (0.8) 3 (0.4) 4 (0.5) 2 (0.2) |